Zelira Therapeutics Limited

ASX:ZLD Voorraadrapport

Marktkapitalisatie: AU$7.9m

Zelira Therapeutics Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Zelira Therapeutics's earnings have been declining at an average annual rate of -41.7%, while the Pharmaceuticals industry saw earnings growing at 35.4% annually. Revenues have been declining at an average rate of 3.5% per year.

Belangrijke informatie

-41.7%

Groei van de winst

-20.6%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie31.2%
Inkomstengroei-3.5%
Rendement op eigen vermogenn/a
Nettomarge-38,513.0%
Laatste winstupdate30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Zelira Therapeutics Limited's (ASX:ZLD) CEO Will Probably Find It Hard To See A Huge Raise This Year

Nov 08
Zelira Therapeutics Limited's (ASX:ZLD) CEO Will Probably Find It Hard To See A Huge Raise This Year

Is Zelira Therapeutics (ASX:ZLD) In A Good Position To Invest In Growth?

Jul 14
Is Zelira Therapeutics (ASX:ZLD) In A Good Position To Invest In Growth?

Here's Why Zelira Therapeutics (ASX:ZLD) Must Use Its Cash Wisely

Jan 19
Here's Why Zelira Therapeutics (ASX:ZLD) Must Use Its Cash Wisely

Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?

Sep 25
Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?

Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?

Jun 03
Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?

A Quick Analysis On Zelira Therapeutics' (ASX:ZLD) CEO Compensation

Dec 31
A Quick Analysis On Zelira Therapeutics' (ASX:ZLD) CEO Compensation

Opbrengsten en kosten

Hoe Zelira Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

ASX:ZLD Opbrengsten, kosten en inkomsten (AUD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 240-3723
31 Mar 240-3632
31 Dec 230-3641
30 Sep 230-2141
30 Jun 230-651
31 Mar 231-882
31 Dec 221-10102
30 Sep 221-11112
30 Jun 222-12121
31 Mar 221-11101
31 Dec 211-1081
30 Sep 211-982
30 Jun 211-972
31 Mar 210-863
31 Dec 200-854
30 Sep 200-854
30 Jun 200-744
31 Mar 200-633
31 Dec 191-433
30 Sep 191-423
30 Jun 191-422
31 Mar 191-312
31 Dec 180-312
30 Sep 180-312
30 Jun 180-212
31 Mar 180-212
31 Dec 170-211
30 Sep 170-411
30 Jun 170-621
31 Dec 160-520
30 Jun 160000

Kwaliteitswinsten: ZLD is currently unprofitable.

Groeiende winstmarge: ZLD is currently unprofitable.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: ZLD is unprofitable, and losses have increased over the past 5 years at a rate of 41.7% per year.

Versnelling van de groei: Unable to compare ZLD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: ZLD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (46.5%).


Rendement op eigen vermogen

Hoge ROE: ZLD's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden